SecBot SecBot
8-K ·Filed Mar 5, 2026

PHIO

Phio Pharmaceuticals Corp.
MIXED
Impact 6/10
Horizonmonths Processed8mo ago SEC0001437749-26-007071
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The increased cash runway reduces near-term dilution risk, but the growing net loss indicates continued burn rate. Monitor upcoming FDA submission in Q2 2026 for PH-762 as the next catalyst.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.16
T+0 close · Mar 5, 2026 · via day close
Latest settled
−2.59%
T+60 · $1.13
Vs SPY
−15.37%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 6 $1.16entry
  2. T+1 · 8mo ago +4.31%α +3.46% · $1.21
  3. T+5 · 8mo ago +0.86%α +2.39% · $1.17
  4. T+20 · 8mo ago +8.62%α +10.67% · $1.26
  5. T+60 · 6mo ago −2.59%α −15.37% · $1.13
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Phio Pharmaceuticals reported its 2025 financial results, highlighting a successful year with completion of the PH-762 Phase 1b trial, $23.7 million in net proceeds from financings and warrant exercises, and an extended cash runway into the first half of 2027. The company reported a net loss of $8.7 million for 2025, up from $7.2 million in 2024, due to increased R&D and G&A spending.

Key Financial Metrics

EPS
$-1.45

Key Facts

  • Completed Phase 1b dose-escalation trial for lead candidate PH-762 with favorable safety and tolerability data
  • Raised $23.7 million in net proceeds during 2025 through equity financings and warrant exercises
  • Cash position increased to $21.0 million at year-end 2025 from $5.4 million at year-end 2024
  • Cash runway extended into the first half of 2027
  • Net loss increased to $8.7 million in 2025 from $7.2 million in 2024
  • R&D expenses increased 27% year-over-year; G&A expenses increased 23% year-over-year

Financial Impact

Net loss increased by $1.55 million year-over-year, while cash position grew by $15.6 million due to financings

net losscash positionR&D expensesG&A expenses

Risk Factors

  • Continuing net losses and cash burn despite recent financing
  • Clinical development risks for PH-762 in later-stage trials
  • Dependence on future financings or partnerships for long-term funding

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001437749-26-007071
Document: phio20251215_8k.htm0001437749-26-007071
Document: 0001437749-26-007071-index-headers.html0001437749-26-007071
Document: 0001437749-26-007071-index.html0001437749-26-007071
Document: 0001437749-26-007071.txt0001437749-26-007071

Track record

7 reports on PHIO

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 5, 202611d ago 8-K Bearish 5/10 Entry $0.8013 to $0.7710 Now $0.7520 +6.15% ▲ +3.78% +6.38% vs SPY
  2. Oct 13, 20264w ago 8-K Neutral 3/10 Entry $0.9345 to $0.8921 Now $0.7520 −19.53% ▼ −4.54% −3.39% vs SPY
  3. Sep 14, 20269w ago 8-K Bullish 5/10 Entry $1.03 to $1.01 Now $0.7520 −26.99% ▼ −1.94% −2.05% vs SPY
  4. Aug 14, 202613w ago DEFA14A Neutral 3/10 Entry $1.06 to $1.17 Now $0.7520 −29.06% ▲ +10.38% +11.57% vs SPY
  5. Apr 8, 202631w ago 8-K Neutral 5/10 Entry $1.25 to $1.27 Now $0.7520 −39.84% ▲ +1.60% −1.59% vs SPY
  6. Apr 8, 202631w ago 424B5 Neutral 5/10 Entry $1.25 to $1.27 Now $0.7520 −39.84% ▲ +1.60% −1.59% vs SPY
  7. Mar 5, 202636w ago 8-K Mixed 6/10 Viewing Entry $1.16 to $1.17 Now $0.7520 −35.17% ▲ +0.86% +2.39% vs SPY
Showing 7 of 7

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 5, 2026